Perspective
Myeloma Bone Disease

Ralph D. Sanderson1 and Joshua Epstein2

Address correspondence to: Ralph D. Sanderson, PhD, Department of Pathology, 1530 3rd Avenue S., SHEL 814, University of Alabama at Birmingham, Birmingham, AL 35294, USA, E-mail: sanderson@uab.edu

INTRODUCTION

Found in >80% of newly diagnosed patients, osteolytic bone disease is one of the most debilitating manifestations of myeloma.1 It dramatically impacts patient quality of life through severe pain, fractures, and spinal cord compression, with resulting neurological pathologies. The severity of myeloma bone disease is reflected in the fact that 40–60% of patients suffer from a bone fracture during the course of their disease, higher than that of other major cancers that metastasize to bone (e.g., breast and prostate cancer).2,3 Bone destruction also releases factors that drive tumor growth, further stimulating disease progression.4 Thus, it is not surprising that high levels of tumor-induced bone resorption is a strong indicator of poor overall survival of myeloma patients.5

Although advances in the understanding of myeloma bone disease have led to promising new therapies, important questions linger. Bone loss in myeloma results from the uncoupling of the mechanisms that control normal bone degradation and bone formation. Overall, myeloma-related bone disease results from the systemic acceleration of bone turnover together with local suppression of osteoblast activity.6 Early in myeloma progression, there is an elevation of both bone-degrading (osteoclast) and bone-forming (osteoblast) activity. However, as the disease progresses, osteoblast activity is suppressed, shifting the balance to a net increase in bone loss.7 Although widespread systemic bone loss in myeloma patients occurs, the most dramatic manifestation is the focal lesions that appear as “holes” on X-rays. This results from local suppression of osteoblasts by myeloma cells leaving only osteoclasts, which, in the absence of osteoblast activity, damage bone beyond repair. In contrast, in the small minority of patients that do not exhibit lytic bone disease, the osteoblasts adjacent to myeloma tumor cells remain active. This review focuses on the mechanisms that are responsible for bone loss in myeloma with emphasis on stimulation of osteoclastogenesis and inhibition of osteoblastogenesis. Also included is a brief description of how myeloma bone disease is diagnosed and a summary of current treatments for preserving bone in patients with this cancer.

HYPERSTIMULATION OF OSTEOCLASTOGENESIS

In myeloma, osteoclasts are hyperstimulated predominantly because of dysregulation of three TNF family members: RANK, its ligand (RANKL), and osteoprotegerin (OPG). The binding of RANKL to RANK that is present on the surface of myeloid precursors is needed for differentiation of the precursors into osteoclasts. The activation of RANK is antagonized when soluble OPG binds to RANKL, thereby preventing RANK activation of RANK. This dampens the rate of osteoclastogenesis. In normal bone, the RANK/RANKL/OPG system works in concert to balance bone turnover and maintain normal homeostasis. In myeloma, both the tumor cells and the bone marrow stromal cells can produce osteoclast-activating factors, thereby shifting the balance toward enhanced osteoclastogenesis and bone destruction. This often occurs within the local tumor microenvironment where osteoclast numbers are seen to be elevated in areas adjacent to myeloma tumor cells. RANKL production is elevated in the bone marrow stroma in myeloma, and in addition, the tumor cells can also express RANKL(8–13) (Fig. 1). High expression levels of membrane-associated RANKL on myeloma cells has been correlated with the presence of multiple bone lesions in myeloma patients.12,13 In addition, the membrane form of RANKL can be released by proteases. This released, soluble form of RANKL can diffuse away from the local tumor environment to promote widespread osteoclast activation, thereby contributing to systemic bone loss in myeloma.14 Interestingly, although myeloma cells do not produce OPG, they can diminish the effect that OPG has on inhibiting osteoclastogenesis. This occurs when the heparan sulfate proteoglycan syndecan-1 on the surface of myeloma cells binds to OPG, leading to internalization and degradation of the OPG.15 Because syndecan-1 is expressed at high levels on most myeloma tumor cells, the binding and degradation of OPG may be a substantial contributor to the bone-degrading phenotype.

The authors state that they have no conflicts of interest.

1Department of Pathology, Center for Metabolic Bone Disease and Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA; 2Department of Medicine, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
of myeloma. Moreover, clipping of the heparan sulfate chains of syndecan-1 by heparanase is associated with increased shedding, MMP-9 and VEGF expression, and elevated angiogenesis, events that may also fuel osteolysis.\(^{(16-18)}\) This is consistent with a reported positive correlation between MMP-9 and VEGF levels and bone lesion score in myeloma patients.\(^{(19)}\)

A number of other effectors have been shown to impact osteolysis including MIP-1\(\alpha\), MIP-1\(\beta\), SDF-1\(\alpha\)/CXCR4, IL-3, IL-6, IL-11, and hepatocyte growth factor. Of these, MIP-1\(\alpha\) has emerged as a major mediator of myeloma bone destruction. This chemokine is produced by myeloma cells and promotes osteoclastogenesis, and its presence at high levels within the serum of myeloma patients correlates with extensive bone disease and poor survival.\(^{(20-23)}\) Gene array profiling indicates that \(MIP-1\alpha\) is the gene that is most highly correlated with osteolysis in myeloma patients.\(^{(24)}\) Although the mechanisms of MIP-1\(\alpha\)-stimulated osteoclastogenesis remain unclear, the finding that RANK knockout mice fail to show enhanced osteoclast formation in calvariae treated with MIP-1\(\alpha\) suggests that this chemokine may act through modulation of RANK.\(^{(25)}\) However, another study concluded that MIP-1\(\alpha\) increases osteoclastogenesis independently of RANK.\(^{(21)}\) Nonetheless, an important role for MIP-1\(\alpha\) in myeloma bone disease has been confirmed by studies in animal models showing that inhibition of MIP-1\(\alpha\) expression or blocking its function with antibodies significantly inhibited osteolysis and tumor burden.\(^{(26,27)}\)

In addition to osteoclast-mediated destruction of bone, some tumor cells may have the capacity to directly degrade bone. It was discovered many years ago that murine plasmacytoma cells can directly degrade bone in the absence of osteoclasts.\(^{(28)}\) More recently, it was shown that some human myeloma cells acquire the functional properties of osteoclasts and degrade bone.\(^{(29-31)}\) The ability of tumor cells to directly degrade bone was found to correlate with expression of \(\alpha\)\(\nu\)\(\beta\)3 integrin, and silencing of \(\beta3\) integrin inhibited the osteolysis in vitro.\(^{(32)}\) This suggests that \(\alpha\)\(\nu\)\(\beta3\) integrin on myeloma cells, in addition to enhancing myeloma cell invasiveness,\(^{(33)}\) may also facilitate osteolysis. It will be important to learn more about direct tumor cell destruction of bone to better assess the effectiveness of therapies directed toward inhibiting osteoclast-mediated bone destruction.

Hyperstimulation of osteoclasts in addition to promoting bone destruction also helps drive further tumor progression. Cell–cell contact between myeloma tumor cells and osteoclasts causes release of factors such as IL-6 and osteopontin that support myeloma growth.\(^{(9,20)}\) Osteoclasts also release angiogenic factors (including osteopontin) that work in concert with other bone marrow factors to enhance angiogenesis.\(^{(34)}\) This link between bone turnover and angiogenesis may be one reason that myeloma presents as such a highly angiogenic disease and may also explain the high rate of relapse and chemoresistance characteristic of myeloma.

### INHIBITION OF OSTEOBLAST DIFFERENTIATION

Bone formation requires proper differentiation of bone marrow mesenchymal stem cells into osteoblasts,
a process that is dependent on the canonical wingless (Wnt) signaling pathway.\(^{35}\) Signaling occurs when Wnt binds to receptors on the cell surface, leading to stabilization of β-catenin in the cell cytoplasm. β-catenin is translocated to the nucleus and stimulates expression of target genes that drive differentiation of the cells into osteoblasts.\(^{36}\) Enhancement of Wnt signaling by lithium chloride treatment or by overexpression of Wnt3a in bone inhibited bone destruction and reduced tumor burden in a murine model of myeloma.\(^{37,38}\) Myeloma cells interfere with Wnt-mediated bone formation by secreting DKK-1, a protein that binds to Wnt receptors and competes with Wnt binding to its receptor (Fig. 1). Interestingly, in addition to inhibiting osteoblast differentiation, DKK-1 can also facilitate osteoclastogenesis by enhancing RANKL/ RANK and macrophage-colony stimulating factor (M-CSF)/c-Fms interactions.\(^{39,40}\) Indeed, the ratios of RANKL/OPG in myeloma patients correlate with the extent of bone disease and predict survival.\(^{41,42}\) DKK-1 is elevated in the bone marrow and blood of myeloma patients with osteolytic lesions.\(^{43}\) Serum DKK-1 levels correlate with the extent of lytic bone lesions, and patients without bone lesions were found to have lower DKK-1 levels than patients having bone lesions.\(^{44}\) Beyond these correlative studies, there is mounting evidence that DKK-1 plays a crucial role in regulating bone loss in vivo. For example, transgenic mice overexpressing DKK-1 exhibit osteopenia, whereas reduction of DKK-1 expression increases bone mass.\(^{45,46}\) Also, antibodies to DKK-1 have been shown to reduce osteolytic lesions and tumor burden in animal models of myeloma, thereby confirming the important negative regulatory effect that DKK-1 has on osteoblastogenesis.\(^{47,48}\)

In addition to DKK-1, there is evidence that myeloma cells also secrete another soluble Wnt inhibitor, frizzled-related protein-2 (FRP-2), that may play a role in dysregulation of osteoblast differentiation.\(^{49}\) Secretion of soluble FRP-2 (sFRP-2) was often found in patients having advanced bone lesions. In vitro, exogenous sFRP-2 suppresses BMP-2–induced osteoblast differentiation, whereas immunodepletion of sFRP-2 restores mineralized nodule formation by osteoblasts.\(^{49}\)

**DIAGNOSIS**

As mentioned above, lytic bone disease in myeloma can be systemic (general osteopenia) and focal. Whereas biochemical markers have been suggested as diagnostic parameters of myeloma-associated osteolysis,\(^{50-55}\) these cannot differentiate between focal and systemic bone loss. Systemic bone loss can be diagnosed with bone densitometry measurements or even routine metastatic bone surveys (MBSs). The standard of diagnosis of myeloma bone disease is by means of radiography. Focal osteolytic lesions develop in areas of focal myeloma growth, which are visible on MRI even before the identification of focal osteolysis by standard MBS.\(^{56}\) Standard MBS has the low sensitivity of standard x-radiographs, which require loss of at least 30% of the bone matrix before osteolysis can be recognized. In contrast, helical CT, because of its superior contrast resolution, has the sensitivity to identify focal bone loss in the majority of cases where MBS failed.\(^{57}\) CT is thus the modality of choice to diagnose focal bone loss in myeloma.\(^{57-59}\)

**TREATMENT**

Myeloma-associated osteolytic lesions do not repair, even in patients in complete remission for many years. The bisphosphonates, which continue to be the standard of care for the treatment of myeloma bone disease, prevent further bone loss by inhibiting osteoclast activity, but these decrease skeletal related events by only 50%. In addition, 4–6% of patients receiving bisphosphonates develop osteonecrosis of the jaw, and often treatment has to be stopped because of kidney toxicity.\(^{4,60}\) Thus, treatments with better efficacy and fewer side effects than bisphosphonates are needed.

The proteasome inhibitors, particularly bortezomib (Velcade: Millennium Pharmaceuticals, Cambridge, MA, USA), have emerged as important bone-preserving agents in myeloma. Although introduced as a therapeutic strategy to inhibit myeloma growth, bortezomib has an important positive impact on bone, and this might contribute to the overall antmyeloma affect of the compound. Bortezomib was shown to reduce tumor burden and enhance BMD in an animal model of myeloma\(^{61}\) and to promote osteoblast differentiation through Wnt-independent activation of β-catenin.\(^{62}\) In clinical studies of relapsed myeloma patients, bortezomib was shown to reduce DKK-1 and RANKL levels, reflecting its potential for mediating important bone protective effects even in advanced disease.\(^{63}\) Proteasome inhibitors can have important anabolic effects on bone as supported by patients that show an increase in markers of osteoblast activity such as alkaline phosphatase and osteocalcin.\(^{64-66}\) A recent report showed that the hydroxamate-based histone deacetylase inhibitor JNJ-26481585, when used in combination with bortezomib, significantly reduced tumor burden, angiogenesis, and myeloma bone disease, including a pronounced reduction of osteoclasts and increase of osteoblasts, trabecular bone volume, and trabecular number.\(^{67}\) This underscores the need to explore bortezomib in combination with various anticancer therapies to find the best therapeutic approach for preserving and building bone.

Another promising approach for treating myeloma bone disease is anti-RANKL therapy using the humanized monoclonal antibody denosumab. This antibody is highly specific for RANKL and effectively blocks the interaction of RANKL with RANK, thereby diminishing osteoclastogenesis. A phase I clinical trial of denosumab in myeloma patients indicated that the antibody suppresses bone resorption without obvious negative side effects.\(^{68}\) Further studies that include larger numbers patients and longer follow-up are needed to determine the usefulness of this antibody against myeloma bone disease.

As described above, DKK1 is central to myeloma bone disease. The lack of repair of myeloma-induced osteolytic lesions likely reflects the continued secretion of
DKK1 by dormant myeloma cells in focal lesions, even in patients in complete remission and after resolution of MRI focal lesions. Inhibition of Dkk1 by monoclonal antibody effectively increased osteoblast numbers and activity in mouse models of myeloma, increased BMD of mouse bones and human bone implants, and reduced tumor burden in most experiments. These results raise hope for a treatment that will repair myeloma osteolytic lesions. Antibodies against DKK1 are currently in early clinical trials. Regarding repair of osteolytic lesions, there is also potential for use of mesenchymal stem cells. These cells, when injected into bone, have been shown to inhibit myeloma tumor growth and increase BMD in an animal model. This type of cell-based therapy could be of great value to treat myeloma patients, particularly if the cells could be engineered to home specifically to myeloma bone lesions after intravenous delivery.

SUMMARY

Bone disease is a characteristic feature of myeloma and causes devastating side effects that impact patient quality of life and survival. New findings over the last several years have led to a better understanding of the molecular mechanisms regulating bone disease including the understanding that myeloma bone disease results from hyperstimulation of osteoclastogenesis and inhibition of osteoblastogenesis. From these mechanistic findings, promising new therapies including bortezomib and denosumab have evolved and give hope for lessening the impact of osteolytic bone disease in myeloma. New therapies such as anti-DKK1 antibodies are on the horizon. Despite these advances, lingering questions remain that need to be addressed. Why in a small minority of patients do osteoblasts near tumor foci continue to survive and proliferate, whereas in most patients osteoblastogenesis is inhibited? Can combinations of bone preserving and bone forming therapies lead to repair of osteolytic lesions in myeloma? To what extent do myeloma tumor cells exhibit direct osteolytic effects separate from osteoclasts, and how can these effects be diminished? Tackling these and other remaining mechanistic questions will lead to even better therapeutic approaches to controlling myeloma bone disease.

ACKNOWLEDGMENTS

This work was supported by NIH Grants CA135075 and CA138340 to R.D.S. and NIH Grants CA55819 and CA113992 to J.E.

REFERENCES

1. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR 2003 Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21–33.
2. Melton LJ III, Rajkumar SV, Khosla S, Achenbach SJ, Oberg AL, Kyle RA 2004 Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res 19:25–30.
3. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R 2007 Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110:1860–1867.
4. Edwards CM, Zhuang J, Mundy GR 2008 The pathogenesis of the bone disease of multiple myeloma. Bone 42:1007–1013.
5. Jakob C, Sterz J, Liebsch P, Mieth M, Rademacher J, Goerke A, Heider U, Fleissner C, Kaiser M, von Metzler I, Muller C, Sezer O 2008 Incorporation of the bone marker carboxy-terminal telopeptide of type-I collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma. Leukemia 22:1767–1772.
6. Bataille R, Chappard D, Marcelli C, Dessauw P, Sany J, Balder P, Alexandre C 1989 Mechanisms of bone destruction in multiple myeloma: The importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 7:1909–1914.
7. Bataille R, Chappard D, Marcelli C, Dessauw P, Balder P, Sany J, Alexandre C 1991 Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 88:62–66.
8. Lai FPL, Cole-Sinclair M, Cheng W-J, Quinn IMW, Gillespie MT, Sentry JW, Schneider H-G 2004 Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. Br J Haematol 126:192–201.
9. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J 2002 Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 116:278–290.
10. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liao DF, Colman N, Michaeli J, Epstein J, Choi Y 2001 Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 98:11581–11586.
11. Barille-Nion S, Bataille R 2003 New insights in myeloma-induced osteolysis. Leuk Lymphoma 44:1463–1467.
12. Heider U, Langelotz C, Jakob C, Zavrsni I, Fleissner C, Eucker J, Possinger K, Holzbauer LC, Sezer O 2003 Expression of receptor activator of nuclear factor [kappa]B ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 9:1436–1440.
13. Farrugia AN, Atkins GJ, To LB, Pan B, Horyvath N, Kostakis P, Findlay DM, Bardy P, Zannettino ACW 2003 Receptor activator of nuclear factor-[kappa]B ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 63:5438–5445.
14. Wilson TJ, Nannuru KC, Futakuchi M, Sadanandam A, Singh RK 2008 Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-[kappa]B ligand. Cancer Res 68:5803–5811.
15. Standal T, Seidel C, Hjertner O, Plesner T, Sanderson RD, Waage A, Borset M, Sundan A 2002 Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 100:3002–3007.
16. Purushothaman A, Chen L, Yang Y, Sanderson RD 2008 Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem 283:32628–32636.
17. Kelly T, Miao HQ, Yang Y, Navarro E, Kusie P, Huang Y, MacLeod V, Cassiano J, Joseph L, Zhan F, Zangiari M, Barlogie B, Shaughnessy J, Sanderson RD 2003 High heparanase activity in multiple myeloma is associated with elevated microvesSEL density. Cancer Res 63:8749–8756.
18. Kelly T, Suva LJ, Huang Y, Macleod V, Miao HQ, Walker RC, Sanderson RD 2005 Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. Cancer Res 65:5778–5784.
19. Alexandrakis MG, Sfiridaki A, Miyakis S, Pappa C, Kandidaki E, Alegakis A, Margioris AN 2007 Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical
markers of bone disease in multiple myeloma. Clin Chim Acta 379:31–35.

Abé M, Hiura K, Wilde J, Shioyosono A, Moriyama K, Hashimoto T, Kido S, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T 2004 Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: A vicious cycle between bone destruction and myeloma expansion. Blood 104:2484–2491.

Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD 2001 Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappab ligand. Blood 97:3349–3353.

Hashimoto T, Abe M, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T 2004 Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol 125:38–41.

Terpos E, Politou M, Szydlo R, Goldman JM, Apperley JF, Rahemtulla A 2003 Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol 123:106–109.

Magrangas F, Naser V, Avet-Loiseau H, Loriod B, Dexeux O, Granjeaud S, Bertucci F, Birnbaum D, Nguyen C, Harousseau JL, Bataille R, Hougatte R, Minville S 2003 Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood 101:4998–5006.

Oyajobi BO, Franchin G, Williams PJ, Pulkrabek D, Gupta A, Munoz S, Grubbs B, Zhao M, Chen D, Sherry B, Mundy GR 2003 Dual effects of macrophage inflammatory protein-1 alpha on osteosclerosis and tumor burden in the murine STGMI1 model of myeloma bone disease. Blood 102:311–319.

Alsina M, Boyle B, Devlin RD, Anderson JL, Craig F, Mundy GR, Roodman GD 1996 Development of an in vivo model of human multiple myeloma bone disease. Blood 87:1495–1501.

Choi SJ, Oba Y, Gazitt Y, Alsina M, Cruz J, Anderson J, Roodman GD 2001 Antisenes inhibition of macrophage inflammatory protein-1 alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 108:1833–1841.

McDonald DF, Schofield BH, Prezioso EM, Adams VL, Frondoza CA, Trivedi SM, Craig C, Humphrey RL 1983 Direct bone resorbing activity of murine myeloma cells. Cancer Lett 19:119–124.

Calvani N, Caforio P, Silvestris F, Dammacco F 2005 Functional osteoclast-like transformation of cultured human myeloma cell lines. Br J Haematol 130:926–938.

Calvani N, Silvestris F, Caforio P, Dammacco F 2004 Osteoclast-like cell formation by cultured myeloma B lymphocytes: Role of RANK-L. Leuk Lymphoma 45:377–380.

Andersen TL, Boissy P, Sondergaard TE, Kupischewicz K, Plesner T, Rasmussen T, Haaber J, Kolovraa S, Delaisse JM 2007 Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell clone: A new type of cancer-host partnership? J Pathol 211:10–17.

Tucci M, De Palma R, Lombardi L, Rodolico G, Berrino L, Dammacco F, Silvestris F 2009 Beta 3 Integrin subunit mediates the bone-resorbing function exerted by cultured myeloma plasma cells. Cancer Res 69:6738–6746.

Ria R, Vacca A, Ribatti D, Di Raimondo F, Merchionne F, Dammacco F 2002 Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma. Haematologica 87:836–845.

Tanaka Y, Abe M, Hiasa M, Oda A, Amou H, Nakano A, Takeuchi K, Kitazoe K, Kido S, Inoue D, Moriyama K, Hashimoto T, Ozaki S, Matsumoto T 2007 Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: A role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res 13:816–823.

Day TF, Guo X, Garrett-Beal L, Yang Y 2005 Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenensis. Dev Cell 8:739–750.

Westendorf JJ, Kahler RA, Schroeder TM 2004 Wnt signaling in osteoblasts and bone diseases. Gene 341:19–39.

Edwards CM, Edwards JR, Lwin ST, Esparza J, Oyajobi BO, McCluskey B, Munoz S, Grubbs B, Mundy GR 2008 Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 111:2833–2842.

Qiang YW, Shaughnessy JD Jr, Yacoby S 2008 Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood 112:374–382.

Fujita K-i, Jans S 2007 Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol Cancer 6:71.

Qiang YW, Chen Y, Stephens O, Brown N, Chen B, Epstein J, Barlogie B, Shaughnessy JD Jr 2008 Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: A potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 112:196–207.

Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, Viniou N, Yataganas X, Goldman JM, Rahemtulla A 2003 Soluble receptor activator of nuclear factor kappab ligand-osteoprotegerin ratio predicts survival in multiple myeloma: Proposal for a novel prognostic index. Blood 102:1064–1069.

Goranova-Marina V, Goranov S, Pavlov P, Tzvetkova T 2007 Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations. Haematologica 92:1000–1001.

Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr 2003 The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349:2483–2494.

Kaiser M, Mieth M, Liebisch P, Oberlander R, Rademacher J, Jakob C, Kleeberg L, Fleissner C, Braendle E, Peters M, Stover D, Sezer O, Heider U 2008 Serum concentrations of DKK-1 correlate with the extent of disease in patients in patients with multiple myeloma. Eur J Haematol 80:490–494.

Li J, Sarosi I, Cuttle RC, Pretorius J, Asuncion F, Grisanti M, Morony S, Adamu S, Geng Z, Qiu W, Kosteniuk P, Lacey DL, Simonet WS, Bolon B, Qian X, Shahlovb H, Ominsky MS, Zhe Ke H, Li X, Richards WG 2006 Dkk-1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39:754–766.

Morvan F, Boulukos K, Clement-Lacroix P, Roman Roman S, Suc-Royer I, Vaysseix B, Amant P, Martin P, Pinho S, Pognonec P, Mollat F, Pichereau C, Barbon M, Barawal G 2006 Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 21:934–945.

Yacoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD Jr 2007 Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109:2106–2111.

Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, Shen Z, Patel N, Tai YT, Chauhan D, Mitsiades CS, Prabhala R, Raje N, Anderson KC, Stover DR, Munshi NC, Ettenberg SA, Shen Z, Patel N, Tai YT, Chauhan D, Mitsiades CS, Prabhala R, Raje N, Anderson KC, Stover DR, Munshi NC 2009 Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114:371–379.

Oshima T, Abe M, Asano J, Haru T, Kitazoe K, Sekimoto E, Tanaka Y, Shibata H, Hashimoto T, Ozaki S 2005 Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 106:3160–3165.

Abildgaard N, Brixen K, Eriksen EF, Kristensen JE, Nielsen JL, Heickendorff L 2004 Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica 89:567–577.

Abildgaard N, Brixen K, Kristensen JE, Eriksen EF, Nielsen JL, Heickendorff L 2003 Comparison of five biochemical markers of bone resorption in multiple myeloma: Elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for
early progression of the bone disease during standard chemotherapy. Br J Haematol 120:235–242.

52. Corso A, Arcaini L, Mangiacavalli S, Astori C, Orlandi E, Lorenzi A, Passamonti F, Klerzy C, Pascutto C, Canevari-Sciorati A, Lazzarino M 2001 Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients. Haematologica 86:394–398.

53. Elomaa I, Virkkunen P, Risteli L, Risteli J 1992 Serum concentration of the cross-linked carboxyterminal telopeptide of type-i collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 66:337–341.

54. Jakob C, Zavrski I, Heider U, Brux B, Eucker J, Langelotz C, Sinha P, Possinger K, Sezer O 2002 Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinolone (Dpd)] in MGUS and multiple myeloma. Eur J Haematol 69:37–42.

55. Nawawi H, Samson D, Apperley J, Girgis S 1996 Biochemical bone markers in patients with multiple myeloma. Clin Chim Acta 253:61–77.

56. Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JR Jr, Epstein J, van Hemert R, Erdem E, Hoering A, Crowley J, Ferris E, Hollmig K, van Rhee F, Shaughnessy JD Jr 2009 Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood 113:4319–4330.

57. Epstein J, Walker R 2006 Myeloma and bone disease: The dangerous tango. Clin Adv Hematol Oncol 4:300–306.

58. Kyle RA, Schreiman JS, McLeod RA, Beabow JW 1985 Computed tomography in diagnosis and management of multiple myeloma and its variants. Arch Intern Med 145:1451–1452.

59. Mahnken AH, Wildberger JE, Gehbauer G, Schmitz-Rode T, Blaum M, Fabry U, Gunther RW 2002 Multidetector CT of the spine in multiple myeloma: Comparison with MR imaging and radiography. AJR Am J Roentgenol 178:1429–1436.

60. Roodman GD 2009 Pathogenesis of myeloma bone disease. Leukemia 23:435–441.

61. Pennisi A, Li X, Ling W, Khan S, Zangari M, Yaccoby S 2009 The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol 84:6–14.

62. Qiang YW, Hu B, Chen Y, Zhong Y, Shi B, Barlogie B, Shaughnessy JD Jr 2009 Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood 113:4319–4330.

63. Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli A, Katodritou E, Verrou E, Vervessou EC, Dimopoulos MA, Croucher PJ 2006 Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 135:688–692.

64. Garrett BR, Chen D, Gutierrez G, Zhao M, Escobedo A, Rossini G, Harris SE, Gallwitz W, Kim KB, Hu S, Crews CM, Mundy GR 2003 Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 111:1771–1782.

65. Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, Kang SH, Yaccoby S, Najarian K, Richardson P, Sonneveld P, Tricot G 2005 Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 131:71–73.

66. Shimazaki C, Uchida R, Nakano S, Namura K, Fuchida SI, Okano A, Okamoto M, Inaba T 2005 High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: Possible role of bortezomib on osteoblast differentiation. Leukemia 19:1102–1103.

67. Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, Vande Broek I, De Raeeve H, Coulton L, Van Camp B, Croucher P, Vanderkerken K 2009 Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: Effect on myeloma bone disease in the 5T2MM murine model of myeloma. Cancer Res 69:5307–5311.

68. Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, Holloway D, Peterson MC, Bekker PJ 2006 A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12:1221–1228.

69. Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD Jr, Evans HR, Snowden JA, Stover DR, Vanderkerken K, Croucher PJ 2009 Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 24:425–436.

70. Yaccoby S, Wezeman MJ, Zangari M, Walker R, Cottler-Fox M, Gaddy D, Ling W, Saha R, Barlogie B, Tricot G, Epstein J 2006 Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myeloma-tous mouse model. Haematologica 91:192–199.

Received in original form September 2, 2009; revised form September 11, 2009; accepted September 23, 2009.